Replies to post #810 on GTC Biotherapeutics (fka GTCB)

[shears]

It seems to me that once there is a ready supply of ATryn the research could really take off. Good for GTCB. One could postulate that the research market could potentially exceed the therapeutic market for hereditary disease.